Menu

Blog

Archive for the ‘law’ category: Page 18

May 20, 2023

G7 calls for adoption of international technical standards for AI

Posted by in categories: economics, governance, law, robotics/AI

TOKYO, May 20 (Reuters) — Leaders of the Group of Seven (G7) nations on Saturday called for the development and adoption of international technical standards for trustworthy artificial intelligence (AI) as lawmakers of the rich countries focus on the new technology.

While the G7 leaders, meeting in Hiroshima, Japan, recognised that the approaches to achieving “the common vision and goal of trustworthy AI may vary”, they said in a statement that “the governance of the digital economy should continue to be updated in line with our shared democratic values”.

The agreement came after European Union, which is represented at the G7, inched closer this month to passing legislation to regulate AI technology, potentially the world’s first comprehensive AI law.

May 19, 2023

Nature’s Quantum Secret: Link Discovered Between Photosynthesis and “Fifth State of Matter”

Posted by in categories: biotech/medical, business, engineering, law, policy, quantum physics

University of ChicagoFounded in 1,890, the University of Chicago (UChicago, U of C, or Chicago) is a private research university in Chicago, Illinois. Located on a 217-acre campus in Chicago’s Hyde Park neighborhood, near Lake Michigan, the school holds top-ten positions in various national and international rankings. UChicago is also well known for its professional schools: Pritzker School of Medicine, Booth School of Business, Law School, School of Social Service Administration, Harris School of Public Policy Studies, Divinity School and the Graham School of Continuing Liberal and Professional Studies, and Pritzker School of Molecular Engineering.

May 10, 2023

Tiny Human Brain Tissue Organoids Can’t Be Legally Considered “a Person”

Posted by in categories: biotech/medical, law, neuroscience

Summary: Researchers proposed the need for a legal framework to guide the conversation on whether or not human brain organoids can be considered people.

Brain organoids are grown from stem cells in a lab, mimicking the growth and structure of real brains. However, they do not fulfill the requirements to be considered natural persons, according to the researchers.

The study explores the potential juridical personhood of human brain organoids, and whether they can be considered legal entities.

May 6, 2023

NeaChat Uses OpenAI ChatGPT Version 4 Offering Chinese Users a Cutting-Edge AI Technology Experience

Posted by in categories: education, finance, law, robotics/AI

NeaChat is an AI-powered chatbot developed based on ChatGPT, serving users in various industries such as education, research, finance, healthcare, and law.

Wuhan, China, May 6, 2023 (GLOBE NEWSWIRE) — The NeaChat team is honored to announce that it has obtained access to OpenAI’s latest generation of artificial intelligence language model GPT-4, becoming one of the first teams in China to obtain authorized access to GPT-4 is a powerful AI model with excellent natural language understanding and generation capabilities, with significant improvements in functionality and performance over its predecessor, GPT-3.5.

The core advantages of GPT-4 lie in its vast knowledge base, efficient problem-solving capabilities, natural language generation, and wide range of applications. We believe that the introduction of GPT-4 will bring a richer and more intelligent experience to NeaChat users.

May 6, 2023

Quantum Computing Supremacy Unleashed: AI Chatbots Are Doomed

Posted by in categories: law, quantum physics, robotics/AI

Artificial intelligence (AI) has become commonplace, and quantum computing is set to alter the landscape radically. The potential of quantum computers to process vast amounts of data at unprecedented speeds could render existing AI chatbots, such as ChatGPT, obsolete.

The intricacies of quantum computing intertwine with understanding the evolution of artificial intelligence. This journey reveals the convergence of two transformative technologies, uncovers challenges, opens opportunities, and underscores the vital role of safeguarding innovations through patent law.

Continue reading “Quantum Computing Supremacy Unleashed: AI Chatbots Are Doomed” »

May 4, 2023

Hugging Face and ServiceNow release a free code-generating model

Posted by in categories: cybercrime/malcode, law, robotics/AI

AI startup Hugging Face and ServiceNow Research, ServiceNow’s R&D division, have released StarCoder, a free alternative to code-generating AI systems along the lines of GitHub’s Copilot.

Code-generating systems like DeepMind’s AlphaCode; Amazon’s CodeWhisperer; and OpenAI’s Codex, which powers Copilot, provide a tantalizing glimpse at what’s possible with AI within the realm of computer programming. Assuming the ethical, technical and legal issues are someday ironed out (and AI-powered coding tools don’t cause more bugs and security exploits than they solve), they could cut development costs substantially while allowing coders to focus on more creative tasks.

According to a study from the University of Cambridge, at least half of developers’ efforts are spent debugging and not actively programming, which costs the software industry an estimated $312 billion per year. But so far, only a handful of code-generating AI systems have been made freely available to the public — reflecting the commercial incentives of the organizations building them (see: Replit).

May 4, 2023

Case report: Magic mushrooms may induce lasting improvements in color-blind vision

Posted by in categories: biotech/medical, health, law, neuroscience, policy

Researchers at the Department of Psychiatry and Psychology, Center for Behavioral Health, Neurological Institute at the Cleveland Clinic in Ohio have authored a case report on the positive effects of psilocybin on color blindness.

Published in the journal Drug Science, Policy and Law, the researchers highlight some implications surrounding a single reported vision improvement self-study by a colleague and cite other previous reports, illustrating a need to understand better how these psychedelics could be used in therapeutic settings.

Past reports have indicated that people with deficiency (CVD), usually referred to as , experience better color vision after using lysergic acid diethylamide (LSD) or psilocybin (magic mushrooms). There is a lack of scientific evidence for these claims, as researching the effects of these drugs has been highly restricted.

May 3, 2023

Mind-reading machines are here: is it time to worry?

Posted by in categories: bioengineering, ethics, law, neuroscience

Neurotech will bring many amazing positive changes to the world, such as treating ailments like blindness, depression, and epilepsy, giving us superhuman sensory capabilities that allow us to understand the world in new ways, accelerating our ability to cognitively process information, and more. But in an increasingly connected society, neuroprivacy will represent a crucial concern of the future. We must carefully devise legal protections against misuse of “mind reading” technology as well as heavily invest in “neurocybersecurity” R&D to prevent violation of people’s inner thoughts and feelings by authorities and malignant hackers. We can capitalize on the advantages, but we must do establish safety mechanisms as these technologies mature. #neurotechnology #neuroscience #neurotech #computationalbiology #future #brain


Determining how the brain creates meaning from language is enormously difficult, says Francisco Pereira, a neuroscientist at the US National Institute of Mental Health in Bethesda, Maryland. “It’s impressive to see someone pull it off.”‘

‘Wake-up call’

Continue reading “Mind-reading machines are here: is it time to worry?” »

May 2, 2023

Drake’s AI clone is here — and Drake might not be able to stop him

Posted by in categories: law, media & arts, robotics/AI

Major record labels are going after AI-generated songs, arguing copyright infringement. Legal experts say the approach is far from straightforward.

A certain type of music has been inescapable on TikTok in recent weeks: clips of famous musicians covering other artists’ songs, with combinations that read like someone hit the randomizer button. There’s Drake covering singer-songwriter Colbie Caillat, Michael Jackson covering The Weeknd, and Pop Smoke covering Ice Spice’s “In Ha Mood.” The artists don’t actually perform the songs — they’re all generated using artificial intelligence tools. And the resulting videos have racked up tens of millions of views.

Continue reading “Drake’s AI clone is here — and Drake might not be able to stop him” »

May 2, 2023

Pfizer, Astellas Pharma‘ Xtandi combo therapy cuts risk of metastasis, death by 58 percent in prostate cancer

Posted by in categories: biotech/medical, law

“There are patients with localized prostate cancer who undergo prostatectomy or radiation therapy in an attempt to cure their disease, but, unfortunately, some patients will develop BCR,” said Neal Shore, M.D., F.A.C.S., U.S. Chief Medical Officer of Urology and Surgical Oncology, GenesisCare, Director, Carolina Urologic Research Center, and Primary Investigator for the EMBARK study. “Importantly, some patients with BCR are at very high risk for developing metastatic disease, which can lead to a cascade of therapeutic interventions. The clinical goal of BCR therapy is to delay cancer progression and avoid metastatic disease. The MFS results from the EMBARK study demonstrate that this intervention with XTANDI plus leuprolide was statistically significant for patients with high-risk BCR.”

“The EMBARK study is a Phase 3 trial exploring the potential of enzalutamide in patients with non-metastatic hormone-sensitive prostate cancer with high-risk BCR,” said Stephen J. Freedland, M.D., Director of the Center for Integrated Research in Cancer and Lifestyle and the Warschaw Robertson Law Families Chair in Prostate Cancer at Cedars-Sinai Cancer and Co-Principal Investigator of the Clinical Trial. “If approved, we hope to bring a new option to men earlier in the course of their disease.”

Consistent with the study’s primary endpoint, statistically significant and clinically meaningful improvements were also observed in the trial’s key secondary endpoints in both the XTANDI combination and monotherapy arms. Specifically, the XTANDI monotherapy arm demonstrated that treatment with XTANDI reduced the risk of metastasis or death by 37% versus leuprolide plus placebo (HR: 0.63; 95% CI, 0.46–0.87; P=0.0049), meeting its MFS endpoint. Treatment with XTANDI plus leuprolide and XTANDI monotherapy reduced the risk of PSA progression by 93% (HR: 0.07; 95% CI, 0.03–0.14; P0.0001) and 67% (HR: 0.33; 95% CI, 0.23–0.49; P0.0001), respectively, versus placebo plus leuprolide. The progression risk in starting a new antineoplastic therapy was reduced by 64% in those treated with XTANDI plus leuprolide (HR: 0.36; 95% CI, 0.26–0.49; P0.0001) and 46% in those treated with XTANDI monotherapy (HR: 0.54; 95% CI, 0.41–0.71; P0.0001) versus placebo plus leuprolide.

Page 18 of 92First1516171819202122Last